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A mixture of two peptides from gp41 (N36 and C34) forms an a-helical structure that is thought to represent the fusogenic
form of gp41. A human anti-gp41 monoclonal antibody (mAb 98-6), generated from the cells of an infected individual, reacted
poorly with C34, but binding was strongly enhanced when N36 was added, indicating that the mAb reacts with a
conformational epitope present in the fusogenic structure formed by the interaction of peptides N36 and C34. The epitope
recognized by mAb 98-6 was found in lysates of virions on oligomeric forms of gp41 (dimers, trimers, and tetramers). On
infected cells, the epitope was present as oligomers of gp41, as monomers of gp41, and as part of the envelope polyprotein
gp160, obtained after biotinylation of intact cells, which were then lysed and immunoprecipitated with various mAbs. In
lysates of infected cells, the epitope was present as part of both monomeric gp41 and gp160. These studies demonstrate that
infected humans can respond to the fusogenic form of gp41 and that the anti-gp41 mAb studied here recognizes a
conformational epitope formed by the interaction of two regions of gp41, which forms an a-helical bundle. This epitope is
found on several forms of gp41 as it occurs in virions, on the surface of infected cells, and in infected cells. © 2000 Academic
Press
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The outcome of exposure to human immunodeficiency
virus type 1 (HIV-1) and the subsequent survival or de-
velopment of AIDS are affected by humoral and cellular
immune responses against HIV (Haigwood et al., 1998).
Interference with virus entry and subsequent steps of the
virus life cycle by antibodies are thought to be crucial for
vaccine development. The transmembrane protein gp41
of HIV-1 plays a key role in both virus-mediated cell–cell
infection and infection by cell-free virus. A structural
model for the transmembrane proteins of many viruses,
including HIV-1, was proposed: thus, the gp41 region of
HIV-1 includes a highly hydrophobic fusion peptide and a
proposed amphipathic a-helical region (Gallaher et al.,
989). A subsequent study showed a leucine zipper motif
n the corresponding a-helical region (Delwart et al.,
1990), and further investigation using synthetic peptides
revealed that peptide DP107 (aa 553–590), within gp41,
displayed a stable a-helical structure and inhibited virus-
ediated fusion (Wild et al., 1992). The stable a-helical
formation of DP107 was disrupted by mixing it with an-
1 To whom correspondence and reprint requests should be ad-
ressed at Tohoku University, Graduate School of Medicine, Division of
llergy and Infectious Diseases, Internal Medicine, 1-1 Seiryo-cho,
oba-Ku, Sendai 980-8574, Japan. Fax:81-22-717-7156. E-mail:
hattori@int1.med.tohoku.ac.jp.
333other gp41-derived peptide, DP178 (aa 638–673), and
DP178 also inhibited virus infection, but at a much lower
concentration (Wild et al., 1994; Matthews et al., 1994).
Another pair of overlapping peptides, N51 (aa 540–
590) and C43 (aa 624–666) from the corresponding gp41
regions, were also reported to form an a-helical structure
(Lu et al., 1995). Crystallization of two peptides from
these regions, N36 (aa 546–580) and C34 (aa 628–661),
revealed the formation of a-helical bundles with an inte-
rior, parallel coiled-coil trimer of N36 flanked by three
C34 molecules in an antiparallel manner; this structure is
thought to represent the core of the fusion-active form of
gp41 (Chan et al., 1997; Weissenhorn et al., 1997; Tan et
al., 1997). Recently, we reported the association of clini-
cal progression with the decline of anti- DP107 antibod-
ies using sera that were periodically obtained from in-
fected individuals (Hattori et al.,1998). Because the syn-
thetic DP107 showed an a-helical structure, we
speculated that the antibody responses against the fu-
sogenic core of gp41 might be associated with clinical
progression. To study the specific antibody response
against the fusogenic form of gp41 in infected individu-
als, we chose a human anti-gp41 mAb, since it had
previously been shown that the epitope of this anti-gp41
human mAb, 98-6, mapped to a conformational epitope,
which overlaps regions spanned by C34 and DP178
(Gorny et al., 1989; Xu et al., 1991; Sattentau et al., 1991).
Thus, we undertook studies to determine whether this
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334 TANIGUCHI ET AL.mAb recognized an epitope represent on virions and on,
as well as in, infected cells.
RESULTS
CD spectroscopy
The CD spectrum of DP178 indicated its random coil
structure, whereas DP107 showed an a-helical structure
displaying characteristic minima at 208 and 222 nm, as
previously reported. The addition of DP178 to DP107
caused a disruption of the a-helical structure of DP107
Fig. 1A) (Wild et al., 1992, 1994; Matthews et al., 1994).
he CD spectra of N36 and C34 showed little secondary
tructure, whereas the CD spectrum of an equimolar
ixture of the N36 and C34 peptides was typical of an
a-helix (Fig. 1B). These findings support previous find-
ings that the mixture of N36 and C34 results in a complex
that approximates the gp41 fusogenic core structure
(Chan et al., 1997; Weissenhorn et al., 1997; Tan et al.,
997).
LISA
We determined whether anti-gp41 mAbs 2F5, 50-69,
nd 98-6 bound to wells coated with the synthetic pep-
ides or recombinant proteins (Fig. 2). mAb 2F5, which
eacts with a conserved linear epitope in gp41, bound to
P178 and to the recombinant envelope protein env 10
nd env 686. mAb 50-69 did not react with DP107 or with
P178, but reacted with both recombinant proteins. mAb
8-6 reacted poorly with DP178 and reacted moderately
ith env 686 and env 10. It was previously shown that
FIG. 1. CD spectra for peptides and their mixture. The peptide was
concentration of 5 mM in PBS and equimolar concentrations of a mixt
was recorded using 1-cm cells at 1-nm intervals, with five scans avera
their mixture.Ab 2F5 reacts with a linear sequence, whereas mAbs
8-6 and 50-69 react with conformational epitopes (Xu etl., 1991; Muster et al., 1993). In addition, the epitope of
8-6 had been localized to a conformational epitope
ocated within the region spanning DP178 and C34 (Xu et
l., 1991), and has recently been shown to react with
eptide C43 (aa 624–666) with the N51-C43 a-helical
complex (Gorny and Zolla-Pazner, 2000) with infected
cells and with intact virions (Zolla-Pazner et al., 1989;
Pinter et al., 1989; Sattentau et al., 1995; and unpublished
results). To characterize its binding to DP107, DP178, or a
mixture thereof, these peptides were coated onto plates,
and the presence of each peptide was confirmed by the
binding of anti-N36 or anti-C34 antibodies. mAb 98-6 did
not react with DP107 alone and reacted poorly to plates
coated with DP178 alone or with the mixture of DP107
and DP178 (Fig. 3, upper panel). The peptides N36 and
C34 and their mixture were coated onto plates, and the
presence of both N36 and C34 on the plates was again
confirmed with the relevant rabbit antibodies. Anti-N36
antibody gave essentially similar reactivities to the wells
coated with N36 alone and with the mixture. Anti-C34
antibody gave different profiles; the peptide mixture gave
a lower reactivity compared to C34 alone. These data,
however, demonstrate that comparable amounts of both
N36 and C34 were coated onto the plates. mAb 98-6
bound to C34 very weakly, although the binding was
markedly enhanced to the peptide mixture (Fig. 3, lower
panel). These findings confirm that mAb 98-6 recognizes
a conformational epitope present in the a-helical core
structure formed by these two peptides.
Western blot with virion antigens
d and activated at 37°C for 10 min. The peptides were diluted at a
wo peptides were made by incubating 1 h at 37°C. CD spectroscopy
r each. (A) DP107 and DP178, and their mixture. (B) N36 and C34, andthawe
ure of tWe subsequently investigated whether mAb 98-6
could recognize the oligomeric forms of gp41 (Chan et
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335CONFORMATIONAL EPITOPE OF mAb 98-6al., 1997; Weissenhorn et al., 1997; Tan et al., 1997;
Zolla-Pazner et al., 1989; Pinter et al., 1989; Sattentau et
l., 1995). Commercially available purified virus lysates
ere used for analysis, as was Chessie 8, a mouse mAb
gainst the gp41 cytoplasmic region, which reacts with
onomeric, dimeric, trimeric, and tetrameric forms of
p41 (Fig. 4). The densitometric analysis of the Chessie
FIG. 2. ELISA data for the binding of human monoclonal antibodies to
with either recombinant proteins or peptides. Recombinant proteins (En
11.4 mM KH2PO4, 0.1% chloroacetamide, 2 mM EDTA, 0.002% BSA), and
t 1 mM. A 100-ml aliquot of each solution was coated at 4°C overnigh
well was blocked with T-PBS containing 1% BSA for 1 h at 37°C. After
diluted with T-PBS containing 1% BSA were added to each well, follo
peroxidase-conjugated anti-human Ig (Cappell Laboratories, Cochranv
ound antibodies were visualized and read as described under Mater
FIG. 3. Binding of anti-peptide rabbit antibodies and 98-6 human m
olumes of each peptide (20 mM) in PBS (40 mM, pH 7.2) and by incub
0 times with PBS and nonmixed peptide (1 mM) was diluted with the sam
ssentially with the same method as described in the legend for Fig. 2 and per
or anti-N36 and anti-C34 antibodies. Upper panel: DP107, E; DP178, ; andbinding pattern showed that the ratio of monomer/
rimer was .2 (Table 1). The data suggest that the bands
een by the Chessie 8 mAb reflect the total amount of
p41, confirming previous results that show that this mAb
ecognizes linear sequences of gp41 (Abacioglu et al.,
994). These results demonstrate that the quantity of
onomeric gp41 in preparations from virus lysates on
binant gp41 or peptides. Each well of a 96-microtiter plate was coated
; Env 10, M) were diluted with coating buffer (pH 7.5, 38 mM Na2HPO4,
tic peptides (DP107, ; DP178, E) were diluted with PBS, respectively,
ed by washing with T-PBS (PBS containing 0.1% Tween 20), and each
g six times with T-PBS, human mAbs or IgG2 control myeloma protein
incubation for 2 h at 37°C. Following washing six times with T-PBS,
was added (105 dilution with T-PBS) and reacted for 1 h at 37°C. The
d Methods.
he peptides and the mixture. The mixture was made by mixing equal
r 1 h at 37°C with occasional gentle shaking. The mixture was diluted
er. The binding of antibodies to the peptide-coated plates was detectedrecom
v686, f
synthe
t, follow
washin
wed byAb to t
ating fo
e buff
oxidase-conjugated anti-rabbit antibody (1:2000, Amersham) was used
the mixture, F. Lower panel: N36, E; C34, ; and the mixture, F.
m
t
r
c
r
m
(
D
336 TANIGUCHI ET AL.these commercial Western blots exceeds the quantity of
the gp41 trimer (120 kDa) and the gp41 tetramer (160
kDa). In contrast, the ratios of binding to gp41 monomer/
trimer and monomer/tetramer with mAb 98-6 were 0.06
and 0.05, and with mAb 50-69 were 0.3 and 0.13, respec-
tively, indicating that these mAbs preferentially react with
oligomers, as described previously (Zolla-Pazner et al.,
1989; Pinter et al., 1989). Only small amounts of gp41
monomers and dimers could be visualized with mAbs
98-6 and 50-69. These findings indicate that the trimers
and tetramers derived from virions and present on com-
mercial Western blot strips optimally possess the 98-6
conformational epitope similar to that displayed by the
fusogenic core structure and that most of the monomeric
and dimeric gp41 on commercial Western blot strips do
not exhibit this structure.
Western blot with antigens from infected cell lysates
To identify whether the epitope recognized by mAb
98-6 could also react with gp41 and with the gp41 portion
of the gp160 precursor found in infected cells, cellular
extracts of H9 cells infected with HTLV-IIIB were exam-
ined. In contrast to the purified viral lysates examined
FIG. 4. Western blot with purified virus. Each strip was incubated
with 2 ml of the buffer (from the manufacturer) containing the antibodies
overnight at room temperature with continuous shaking. After washing
the strips with PBS-T, peroxidase-conjugated species-specific anti-
mouse Ig or anti-human Ig diluted with the same buffers (1:2000) was
added. The bound antibodies were detected by ECL. Lane A: the
positive control reference serum from the manufacturer; lane B:
Chessie 8 (2 mg/ml); lane C: mAb 98-6 (0.9 mg/ml); lane D: mAb 50-69
0.9 mg/ml); and lane E: anti-gp41 human sera (1.5 mg/ml).
TABLE 1
Densitometric Analysis of Western Blot of Purified Viruses
Identified bands Chessie 8 mAb 98-6 mAb 50-69 mAb
gp41 tetramer 20.9a 47.3 49.3
gp41 trimer 21.3 42.9 44.4
gp41 dimer 3.2 2.7 0
gp41 monomer 53.5 2.4 6.2a Percentage of the density of each lane.with commercial Western blots, there were no dimers or
trimers in the cell lysates, but gp41 monomers and the
gp160 precursor were present (Fig. 5 and Table 2). The
densitometric analysis of Western blots developed with
Chessie 8 showed that the ratios of monomeric gp41/
gp160 is ;1 and those developed with 98-6 and 50-69
are similar. These data indicate that both mAb 98-6 and
50-69 can recognize monomeric gp41 and gp160 in cell
lysates, and/or that oligomers in cell lysates were dis-
rupted by the conditions used for these Western blots,
resulting in monomers of gp41 that retained the 98-6
epitope.
Treatment with sCD4
The absence of trimers or tetramers in cell lysates,
and their presence in viral lysates, led us to study the
status of gp41 on the surface of infected cells where
virus assembles prior to budding. The cell surface pro-
teins were labeled by biotinylation and were then lysed
and immunoprecipitated with each of the mAbs (Chessie
8, 50-69, 98-6, and Cb1). Chessie 8 could detect mono-
er, dimer, and trimer as well as gp160 and/or gp41
etramer on the cell surface, giving a monomer/trimer
atio as 0.45 (Fig. 6 and Table 2). mAbs 98-6 and 50-69
ould also precipitate the same bands; however, the
elative proportion of trimer detected by these latter two
Abs was smaller than that detected by Chessie 8. Cb1
served as a control, precipitating only gp160 and gp120
via their V3 loops.
It has been well established that sCD4 treatment en-
hances the exposure of the 98-6 and 50-69 epitopes on
infected cells (Sattentau and Moore, 1991; Sattentau et
al., 1995). To study the relative exposure of various forms
of gp41 after exposure to sCD4, the optimal amount of
sCD4 was added to H9 cells infected with HTLV-IIIB,
FIG. 5. Western blot with infected cell lysates (H9/IIIB). Cell lysates of
H9/IIIB cells (2 3 104 cells/lane) were used for SDS–PAGE followed by
Western blot analysis. The binding of the antibodies was analyzed
using the same method as described in the legend for Fig. 4, and the
final concentrations of the antibodies were 2 mg/ml in 2 ml buffer. Lane
A: normal human serum; lane B: mAb Cb1; lane C: mAb Chessie 8; lane
: mAb 98-6; and lane E: mAb 50-69.followed by biotinylation of the cell surface proteins. This
treatment did not change the amount of each band visu-
ates.
337CONFORMATIONAL EPITOPE OF mAb 98-6alized with Chessie 8. However, the amount of mono-
meric and trimeric gp41 revealed by mAb 98-6 was in-
creased by the brief exposure, as was the amount of
monomeric gp41 detected by 50-69. The data suggest
that the binding of sCD4 to partially or fully assembled
virions on the cell surface results in a conformational
change, which makes the 98-6 and 50-69 epitopes on the
various forms of gp41 more accessible (Fig. 6).
DISCUSSION
Studies of peptides derived from two hydrophobic re-
gions of the ectodomain of gp41 have demonstrated that
gp41 undergoes a dramatic conformational change,
which triggers the fusion of the HIV-1 envelope with the
target cell, leading to the introduction of the HIV-1 nu-
cleocapsid into the cytoplasm of permissive cells (Gal-
laher et al., 1989; Delwart et al., 1990; Wild et al., 1992,
1994; Matthews et al., 1994; Lu et al., 1995; Chan et al.,
1997; Weissenhorn et al., 1997; Tan et al., 1997; Sattentau
and Moore, 1991; Sattentau et al., 1995; Furuta et al.,
1998). The change in gp41 structure is marked by the
formation of a fusogenic structure that consists of a
coiled-coil structure. In the study described earlier, we
demonstrate that this coiled-coil structure exists in vivo,
that it induces an immune response in infected humans,
and that it is probably imbued with novel epitopes, which
do not exist unless two regions of gp41 interact to form
the characteristic a-helical bundle.
Studies of the fusogenic core of gp41 were undertaken
FIG. 6. Effects of soluble CD4 on antigen expression. H9/IIIB cells wer
T
Presence of Different Immunoreactive Form
Monomer Di
Virions 1a 1
Infected cell surface 1 6
Infected cell lysates 1 2
a Definitive positive band.
b Undetermined positive band.
c Not distinguished whether both or only gp160 is present in cell lystwice with PBS followed by biotinylation. Representative data from three diffe
after 15-min exposure of sCD4 are shown.with a human monoclonal antibody, 98-6, because it had
previously been shown that it recognized a conforma-
tional epitope that mapped to a region of gp41 overlap-
ping peptide C34 (Chan et al., 1997; Weissenhorn et al.,
1997; Xu et al., 1991). We first determined whether this
antibody could react with peptides from this region, i.e.,
with C34 or DP178. Although the mAb could recognize
recombinant gp41 proteins strongly, reactivity with these
two linear synthetic peptides was only barely detectable.
However, the reactivity was increased dramatically when
peptide N36 was mixed with peptide C34, although a
similar increase could not be seen when DP107 was
mixed with DP178. This increase in reactivity correlated
with the acquisition of an a-helical structure by the mix-
ture of N36 and C34. The mixture of DP107 and DP178
lacks this structure and lacks reactivity with mAb 98-6.
Given that the a-helical structure assumed by N36 and
C34 is thought to represent the fusogenic core structure
of gp41 (Chan et al., 1997; Weissenhorn et al., 1997; Tan
et al., 1997), these findings strongly indicate that mAb
98-6 recognizes an epitope that exists in the fusogenic
core structure of gp41. Since this mAb was generated
from peripheral blood mononuclear cells of an infected
individual, the coiled-coil structure formed by the mixture
of N36 and C34 represents a structure occurring in vivo,
and the reactivity of human mAb 98-6 with this coiled-coil
suggests that this structure exists and is immunogenic in
humans. Previously, a human recombinant Fab, desig-
nated Fab-d, was reported to react with the novel epitope
red with or without sCD4 for 5–15 min, and obtained cells were washed
p41 in Virions and in and on Infected Cells
Trimer Tetramer gp160
1 1 1
1 1 1
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s of g
mer
brent experiments with similar results are shown. The cells before and
p
p
m
t
(
U
a
i
p
p
s
1
m
A
e
7
338 TANIGUCHI ET AL.induced by a mixture of DP178 and a mixture of DP178-
deleted gp41 (Chen et al., 1995), although it cannot be
determined that this recombinant Fab represents an an-
tibody that actually exists in the human Ig repertoire.
Next, we investigated whether the epitope recognized
by mAb 98-6 is present in various forms of gp41 derived
from lysates of virions, lysates of infected cells, and from
the lysed surface-labeled infected cells. Studies of vari-
ous forms of virion-derived gp41 displayed on commer-
cial Western blots showed that monomers, dimers, trim-
ers, and tetramers of gp41 are present but that the
epitope recognized by mAb 98-6 is primarily present on
only the trimers and tetramers (Fig. 4). In contrast, West-
ern blots using infected cell lysates displayed few
dimers or trimers of gp41 (Fig.5), but monomeric gp41
and gp160 are present. The finding that the 98-6 epitope
is present on the intracytoplasmic monomeric form of
gp41 but not on the monomer from purified viruses could
be attributable to the different methods of preparing
Western blot strips from virions and cell lysates or to
envelope processing as the virus is assembled and
buds. Yet another pattern was detected when gp41 on
the surface of infected cells was studied: immunopre-
cipitation revealed that all forms of gp41 and gp160 were
present on the surface of infected cells, although these
analyses were done using detergent-lysed cells. Further-
more, the increase of 98-6-reactive monomeric gp41 on
the surface of infected cells in the presence of CD4
indicates that this interaction may induce or facilitate the
formation of the fusion-active form of gp41.
A mouse mAb against the fusogenic core structure
(NC-1), induced by immunizing mice with the synthetic
peptides of a stable six-helix bundle, N36(L6)C34, was
recently described. This antibody also reacts with trim-
ers and tetramers of gp41 from purified virus; however,
NC-1 stains the surface of infected cells only in the
presence of sCD4 (Jiang et al., 1998), whereas mAb 98-6
stains the infected cell surface in the absence of sCD4,
although the staining is enhanced in the presence of
sCD4 treatment (Sattentau et al., 1991). These findings
suggest that these two mAbs recognize different
epitopes in the fusogenic structure.
Previous studies have demonstrated that mAb 98-6
has no neutralizing activity against laboratory strains of
HIV-1 and has only limited neutralizing activity against
some primary isolates (Hioe et al., 1997; Forthal et al.,
1995). Recently, mAb 98-6 has been shown to react with
both C43 and the N51-C43 complex, suggesting that this
mAb could be induced by the both the prefusogenic and
the fusogenic forms of gp41 and that antibodies that
efficiently interfere with the formation of the fusogenic
structure, such as mAb 2F5, neutralize more efficiently
(Gorny and Zolla-Pazner, 2000). Further assessment of
the relationships between the neutralizing activity and
knowledge of epitopes would be helpful to design the
p
aantigens that could induce effective neutralizing antibod-
ies.
MATERIALS AND METHODS
Recombinant proteins
Bacterial-derived recombinant gp41 proteins from the
envelope gene of HIV-1 were kindly provided by Dr. Ahn
at Ortho Clinical Diagnostics (Raritan, NJ) and were used
in ELISA. The names and their sequences are env 686
(aa 475–753) and env 10 (aa 549–768). Two hydrophobic
regions (aa 517–543, 680–706) were absent from env 686
(Sayre et al., 1996).
Peptides
Four different peptides (N36, DP107, C34, and DP178)
were synthesized by Peptide Inc. (Osaka, Japan); their
sequences were obtained from HIV-1LAI as described
reviously (Wild et al., 1992, 1994; Chan et al., 1997). The
urity of the peptides was confirmed by high-perfor-
ance liquid chromatography, and ion-spray mass spec-
ra of the peptides was kindly performed by H. Tamamura
Graduate School of Pharmaceutical Sciences, Kyoto
niversity) with a Sciex API IIIE biomolecular mass an-
lyzer (Toronto, Canada) (Tamamura et al., 1998). The
on-spray mass spectra showed that the synthesized
eptides had their theoretical molecular weights. Each
eptide was aliquoted at a concentration of 400 mM,
either in water (DP107, C34) or phosphate-buffered sam-
ple buffer (PBS, pH 7.2, 40 mM sodium phosphate, 150
mM NaCl) (DP178, N36) and stored at 230°C.
CD spectroscopy
The peptides were diluted with PBS at concentrations
of 5 mM. CD spectra were recorded on a JASCO J-720
pectropolarimeter (Tokyo, Japan) using 1-cm cells at
-nm intervals, with five scans averaged for each (Tama-
ura et al., 1998). In some experiments, two peptides
were mixed at a 1:1 ratio at 37°C for 1 h before the
mixture was analyzed by CD spectra.
Monoclonal and polyclonal antibodies
Human mAbs 98-6 and 50-69 were obtained from
Epstein-Barr virus-transformed B-cell cultures derived
from HIV-1-infected persons (Gorny et al., 1989; Xu et al.,
1991). A neutralizing human anti-gp41 mAb, 2F5, specific
for an epitope at aa 662–667 was kindly provided by Dr.
T. Muster (Muster et al., 1993). A mouse/human chimeric
mAb against the gp120 V3 loop, Cb1, was from Dr. Eda at
Chemoserotherapeutic Institute (Matsushita et al., 1992).
mouse mAb, Chessie 8, which reacts with a linear
pitope in the intracytoplasmic domain of gp41 (aa 727–
32) that survives alkylation and reduction was kindly
rovided by Dr. G. Lewis through the NIH AIDS Research
nd Reference Reagent Program (Abacioglu et al., 1994).
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339CONFORMATIONAL EPITOPE OF mAb 98-6Polyclonal antibodies against N36 or C34 that were gen-
erated by immunizing NZW rabbits with 200 mg of pep-
ide mixed with equal volumes of complete Freund’s
djuvant were obtained from Dr. C. Weiss at the FDA.
ffinity-purified anti-gp41 human sera and human IgG2
myeloma protein were used as positive and negative
controls, respectively, and these antibodies were pur-
chased from Immuno Diagnostics (Bedford, MA) and
Calbiochem-Novabiochem (San Diego, CA). Mouse IgG1
k myeloma protein (MOPC-21) (Sigma Chemical, St.
ouis, MO) was also used as a negative control.
nzyme-linked immunosorbent assay (ELISA)
Optimal amounts of recombinant proteins or peptides
ere diluted with buffer (1 mM) and were coated onto
96-well ELISA plates as described previously (Hattori et
al., 1998) and in legend for Fig. 2. Each well was blocked
with 250 ml of T-PBS containing 1% bovine serum albu-
in (BSA) for 1 h at 37°C. The plates were washed with
-PBS, followed by incubation either with rabbit or hu-
an anti-HIV or control antibodies. After washing, horse-
adish peroxidase-linked anti-rabbit or -human antibod-
es were added, and the bound antibodies were visual-
zed by a peroxidase reaction at room temperature for 10
in using OPD tablets (Dako A/S, Glostrup, Denmark)
ith 0.006% H2O2. The absorbency was read at 492 nm,
and background values obtained from control antibody
were subtracted as previously described (Hattori et al.,
1998).
Immunoblotting
Commercially available Western blot strips were used
to study viral proteins (Ortho). The conditions for SDS–
PAGE that were used to make these strips were not
disclosed by the manufacturer. To study the viral proteins
in infected cells, H9 cells infected with HTLV-IIIB (H9/IIIB;
kindly provided by Dr. R. C. Gallo) were cultured in RPMI
1640 medium containing streptomycin (100 mg/ml) and
penicillin G (100 U/ml) with 10% fetal calf serum in 5%
CO2 in a humidified atmosphere at 37°C. After washing
hree times with HBSS, the cells (1 3 107) were lysed
with 1 ml of lysis buffer (10 mM Tris–HCl, pH 7.5, 137 mM
NaCl, 1% Triton X-100, and 2 mM PMSF) by incubation for
15 min on ice, and the supernatants were obtained by
centrifugation at 18,000 g for 15 min. The supernatants
were mixed with an equal volume of 23 SDS–sample
buffer (250 mM Tris–HCl, pH 6.8, 2% SDS, 1 mM EDTA,
20% glycerol, and 5% 2-ME) followed by boiling for 3 min.
The components of each sample were separated on 10%
SDS–PAGE followed by Western blotting. The second
antibody used was peroxidase-conjugated affinity-puri-
fied goat F(ab9)2 anti-mouse or anti-human immunoglob-
lin (Biosource, Camarillo, CA). The bound antibodies
ere visualized with enhanced chemiluminescence
ECL; Amersham, Buckinghamshire, U.K.) followed byutoradiography. The intensities of the bands were quan-
ified using a densitometer (PDI system; Huntington Sta-
ion, NY) as described (Zhang et al., 1999).
mmunoprecipitation
H9/IIIB cells (5 3 106 cells/ml) were cultured at 37°C
ith or without baculovirus-derived recombinant soluble
D4 (sCD4; Immuno Diagnostics, Bedford, MA) at a
oncentration of 2.5 mg/ml in RPMI 1640 medium con-
aining 1% FCS for different periods (5, 10, and15 min) as
escribed previously (Maeda et al., 1992). Cell surface
biotinylation and immunoprecipitation were performed
as previously described with slight modifications (Kim et
al., 1994). In brief, cells were washed twice with PBS and
incubated in PBS containing 0.5 mg/ml NHS-L-C-biotin
Pierce, Rockford, IL) at room temperature for 15 min.
ree succinimide groups were then blocked by the ad-
ition of 5 ml of nonsupplemented RPMI 1640 medium at
oom temperature for 5 min. After washing, cells were
ysed in 0.5 ml Triton X-100 lysis buffer (pH 8.0) contain-
ng 20 mM Tris–HCl, 137 mM NaCl, 1% Triton X-100, 137
M NaCl, 2 mM EDTA, and 1 mM PMSF on ice for 20
in. Cell lysates were centrifuged at 15,000 rpm for 20
in, and the supernatants were collected. A 300-ml sam-
le of lysates of labeled cells (;0.5 mg) were precleared
y incubation with 20 ml of protein G-Sepharose (Phar-
acia Biotech AB, Uppsala, Sweden) and with 1 mg
uman IgG2 myeloma protein or mouse IgG1 k MOPC-21
t 4°C for 1 h. After centrifugation for 3 min at 10,000 rpm,
he obtained supernatant was reacted with 1 mg of each
ntibody and with 20 ml of protein G-Sepharose at 4°C
or 1 h. After washing the beads four times with the Triton
-100 lysis buffer, the bound antigens were eluted by
oiling 3 min in SDS–sample buffer (13) and were elec-
rophoresed by SDS–PAGE (10%). The bound antigens
ere visualized by Western blot using horseradish per-
xidase-conjugated streptavidin (Amersham) followed by
CL.
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